ReviewFrontiers in medicine2021
COVID-19 and Sarcoidosis, Readiness for Vaccination: Challenges and Opportunities.
Review in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 20 citations in OpenAlex.
- Infectious Complications of Pulmonary Sarcoidosis.Journal of clinical medicine · 2024Review
- Article
- Initial behaviors and attitudes towards the COVID-19 vaccine in sarcoidosis patients: results of a self-reporting questionnaire.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2023Article
- Sarcoidal Tattoo Granuloma After COVID-19 Vaccine.JAAD case reports · 2023Article
- New-onset lung sarcoidosis, an adverse event by COVID-19 or a sign of convalescence; a case report.Clinical case reports · 2023Article
- Trimer IgG and neutralising antibody response to COVID-19 mRNA vaccination in individuals with sarcoidosis.ERJ open research · 2023Article
- COVID-19 vaccine-induced vasculitis in a patient with sarcoidosis: A case report.Clinical case reports · 2022Article
- Sarcoidosis and COVID-19: At the Cross-Road between Immunopathology and Clinical Manifestation.Biomedicines · 2022Review
- Using bioinformatics and systems biology to discover common pathogenetic processes between sarcoidosis and COVID-19.Gene reports · 2022Article
- Common genetic aspects between COVID-19 and sarcoidosis: A network-based approach using gene expression data.Biochemistry and biophysics reports · 2022Article
- First Report of Two Cases of Löfgren's Syndrome after SARS-CoV-2 Vaccination-Coincidence or Causality?Vaccines · 2021Article
- Cutaneous Adverse Reactions to COVID-19 Vaccines: Insights from an Immuno-Dermatological Perspective.Vaccines · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 7 institutions in 2 countries.
Funding
Abstract
Sarcoidosis is an immune mediated chronic inflammatory disorder that is best characterized by non-caseating granulomas found in one or more affected organs. The COVID-19 pandemic poses a challenge for clinicians caring for sarcoidosis patients who may be at increased risk of infection compared to the general population. With the recent availability of COVID-19 vaccines, it is expected that clinicians raise questions regarding efficacy and safety in sarcoidosis. However, studies examining safety and efficacy of vaccines in sarcoidosis are lacking. In this review, we examine the current literature regarding vaccination in immunocompromised populations and apply them to sarcoidosis patients. The available literature suggests that vaccines are safe and effective in patients with autoimmune disorders and in those taking immunosuppressive medications. We strongly recommend the administration of COVID-19 vaccines in patients with sarcoidosis. We also present a clinical decision algorithm to provide guidance on vaccination of sarcoidosis patients against COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.